血清CA19-9、Hcy、CA50和SA联检对胰腺癌的诊断价值

Diagnostic Values of Combined Measurement of Serum CA19-9,Hcy,CA50 and Sialic Acid in Patients with Pancreatic Cancer

目的:探讨了肿瘤标志物糖类抗原19-9(CA19-9),同型半胱氨酸(Hcy),糖类抗原50(CA50)和唾液酸(SA)联检对胰腺癌的临床评价。方法:应用放免法、免疫法和生化法对32例胰腺癌患者进行了血清CA19-9、Hcy、CA50和SA检测,并与35名正常健康人作比较。结果:以单一指标阳性作为诊断标准,CA19-9、Hcy、CA50和SA对胰腺癌的敏感性分别为68.8%、59.4%、62.5%和46.9%,特异性分别为84.8%、80.6%、71.4%和67.2%,联检二项或二项以上阳性作为标准,本文患者诊断的灵敏度为96.9%,特异性为98.2%。结论:联检血清CA19-9、Hcy、CA50和SA对胰腺癌的辅助诊断有较高的临床实用价值。

Objective To study the diagnostic values of combined measurement of serum CA19-9,Hcy,CA50 and SA levels in patients with pancreatic cancer.Methods Serum CA19-9,CA50（with RIA）,Hcy（with immunity method）,SA（with biochemistry） levels were measured in 32 patients with pancreatic cancer and 35controls.Results As a single tumor marker for diagnosis,the sensitivity of CA19-9,Hcy,CA50 and SA was 68.8%,59.4%,62.5% and 46.9%,respectively,the specificity was 84.8%,80.6%,71.4% and 67.2% individually,with combined detection of the four markers and assumed two or more markers positive as standard the sensitivity and specificity were 96.9%,98.2% respectively.Conclusion Combined measurement of serum CA19-9,Hcy,CA50 and SA levels can be usefull for diagnosis of pancreatic cancer.